Skip to content

速百纳斯制药

US · SUPN #2636 按市值排名 上市于 1970
37.88 -1.69 -4.27%
实时 - 追踪5344个代码 - 心跳于295秒前 · 2026-10-16 19:30

✦ 量化财务健康度 计算方式说明

良好
  • 奥特曼 Z 值为4.55,高于3.0的"安全区"阈值。
  • 该模型对工业和制造业公司最为可靠,对银行、保险等金融类公司参考意义较弱。

营收 年度数据,近8年

最近年度同比+8.63%

利润率

毛利率
89.63%
营业利润率
-5.13%
净利率
-5.36%

关键比率与质量指标

奥特曼 Z 值低于约1.8提示财务困境风险,高于约3.0提示风险较低;该模型对工业和制造业公司最为可靠,对银行等金融类公司参考意义较弱。

利润表

项目 2018 2019 2020 2021 2022 2023 2024 2025
营收 408.90M392.76M520.40M579.78M667.24M607.52M661.82M718.95M
毛利润 393.54M376.10M467.94M504.71M580.02M523.74M583.91M644.39M
销售及管理费用 154.70M153.25M200.68M304.76M377.22M336.36M321.58M485.56M
研发费用 89.21M69.10M75.96M90.47M74.55M91.59M108.80M106.24M
营业利润 144.44M148.57M175.60M79.50M45.61M13.40M75.56M-36.86M
税前利润 140.18M147.49M168.65M73.18M60.74M2.77M97.87M-49.03M
税费 29.18M34.43M41.70M19.75M32.00K1.45M24.01M-10.48M
净利润 110.99M113.06M126.95M53.42M60.71M1.32M73.87M-38.55M
基本每股收益 2221101-1
稀释每股收益 2.052.102.360.981.040.021.32-0.68

资产负债表

项目 2018 2019 2020 2021 2022 2023 2024 2025
流动资产总额 493.49M472.64M630.42M601.59M734.15M493.11M686.07M644.18M
现金及短期投资 356.02M347.07M422.53M339.68M461.33M254.87M453.61M308.67M
存货 25.66M26.63M48.33M85.96M91.54M77.41M54.29M82.39M
总资产 977.81M1.16B1.50B1.69B1.70B1.28B1.37B1.45B
流动负债总额 161.35M160.59M245.11M315.38M687.96M290.20M292.40M338.17M
短期负债 --2.83M3.76M6.48M408.76M8.33M6.89M10.61M
长期负债 329.46M345.17M361.75M379.25M--------
总负债 524,788,000.00564,854,000.00759,244,000.00873,301,000.00816,304,000.00356,157,000.00332,340,000.00390,934,000.00
股东权益总额 453.02M595.43M744.86M815.85M886.20M921.52M1.04B1.06B
留存收益 86.49M199.55M326.50M379.92M481.25M482.56M556.43M517.88M

现金流量表

项目 2018 2019 2020 2021 2022 2023 2024 2025
经营活动现金流 128.99M143.13M138.40M127.13M116.83M111.09M171.95M47.33M
折旧与摊销 7.06M6.66M18.14M32.60M85.54M84.86M80.41M91.56M
自由现金流 128.14M141.74M134.71M125.08M116.41M110.53M171.23M45.99M
已派股息 ----------------
股票回购/发行 11.58M3.93M4.36M7.10M12.42M6.61M14.91M37.62M
期末现金余额 192.25M181.38M288.64M203.43M93.12M75.05M69.33M129.90M

回报与效率指标

项目 2018 2019 2020 2021 2022 2023 2024 2025
净资产收益率 30.8121.5718.946.857.130.157.55-3.68
总资产收益率 15.8310.589.533.353.580.095.58-2.73
投入资本回报率 16.5812.9512.265.233.58-0.416.07-4.51
5年平均净资产收益率 22.6432.8432.3020.6217.0610.938.123.60
息税前利润率 38.7143.3336.9716.6610.160.8514.79-6.82
自由现金流/营收 31.3435.7525.9321.5717.4518.1925.876.40
流动比率 3.062.942.571.911.071.702.351.90
速动比率 2.842.712.301.550.911.382.041.47
资产负债率 33.6932.6227.5525.2826.123.252.512.82
长期负债权益比 72.7363.0855.1251.554.063.602.642.86
利息保障倍数 8.747.508.104.129.592.15----
营收复合年增长率(3年) 40.4922.2419.8612.3419.325.304.512.52
净利润复合年增长率(3年) 99.677.4230.38-21.63-18.72-78.2011.40--
自由现金流复合年增长率(3年) 58.1129.546.15-0.80-6.35-6.3811.03-26.62

营收构成 最近报告期

业务分部

Single segment100.00%

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

速百纳斯制药 讨论区 0 条评论

发表评论